REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc., trading under ticker TZAC, is the publicly listed entity formed through the business combination of Tenzing Acquisition Corp, a blank-check company that completed its IPO in 2021, and clinical-stage biopharmaceutical firm Reviva Pharmaceuticals, which concentrates on central nervous system and metabolic disease therapeutics. Operating in the healthcare and life sciences sector, Tenzing Acquisition Corp filed an 8-K with the SEC on November 14, 2022, representing a material disclosure event in the post-combination period. The de-SPAC transaction brought Reviva's drug development pipeline to public markets through the blank-check vehicle structure. Sign up for full data on SpacDesk to access complete filing histories, deal timelines, and analytics on TZAC and the broader SPAC universe.